T 0205/14 (Ibandronate sodium, Form QQ/TEVA) of 18.06.2015

European Case Law Identifier: ECLI:EP:BA:2015:T020514.20150618
Date of decision: 18 June 2015
Case number: T 0205/14
Petition for review of: -
Application number: 05791142.2
IPC class: A61P 19/10 C07F 9/38 A61K 31/663
Language of proceedings: English
Distribution: No distribution (D)
Download: Decision in English
OJ versions: No OJ links found
Other decisions for this case: -
Abstracts for this decision: -
Application title: CRYSTALLINE FORM OF IBANDRONATE SODIUM AND PROCESSES FOR PREPARATION THEREOF
Applicant name: Teva Pharmaceutical Industries Ltd
Opponent name: Hexal AG
Actavis Group PTC EHF
Pharmathen Industrial S.A.
Board: 3.3.01
Headnote: -
Relevant legal provisions: European Patent Convention Art 54 European Patent Convention Art 56
Keywords: Right of priority - assignment
Main request: novelty (yes), inventive step (no)
Requests AR1-AR5, MRa, AR1a-AR5a: inventive step (no)
Request AR6: admitted (no)
Catchword: -
Cited cases: G 0001/92 G 0003/92 G 0003/99 G 0001/13 R 0016/09 J 0019/87 J 0012/00 J 0002/01 J 0004/10 T 0595/90 T 1008/96 T 0005/05 T 0062/05 T 0788/05 T 0493/06 T 0382/07 T 1933/12 T 0160/13
Citing cases: G 0001/22 G 0002/22 J 0005/23 T 0577/11 T 2466/13 T 0517/14 T 0725/14 T 0969/14 T 1201/14 T 0407/15 T 0924/15 T 1103/15 T 1513/17 T 2431/17 T 1065/18 T 1079/18 T 2719/19 T 0546/21

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The patent is revoked.